The Developmental Research Program of the RPCI-UPCI Ovarian Cancer SPORE is a platform to support innovative, potentially high-risk/high-reward, investigator-initiated projects with the potential for maturation into translational ovarian cancer research projects that will transit basic and/or population research findings into research focused on human clinical specimens/patient populations. Furthermore, the funds of the Developmental Research Program will be leveraged by encouraging the development of the pilot projects into collaborative, multi-investigator, multi-institutional translational research programs, or as replacements for the Individual Research Projects of the RPCI-UPCI Ovarian Cancer SPORE. Therefore, the Developmental Research Program projects are the ultimate measure of the success of a SPORE, and form the base for future translational ovarian cancer research at the individual institutions since they are the springboard for the next generation of R01, P01, Consortium, and SPORE grants. Proposals from faculty with established ovarian cancer research programs, or faculty interested in transitioning to translational ovarian cancer research, will be evaluated by the Executive Committee for scientific merit. The Development Research Program Leaders will convene a NIH format study section and assign NIH R21- type applications to two scientific and one patient advocate reviewers. Review results will be summarized in the Administrative Core and submitted to the Internal Advisory Board for recommendations for funding. The Developmental Research Program will fund three to four projects per year at a funding level of $50,000 per year. Highly promising projects are eligible for an additional year of funding, but in order to maintain maximal flexibility in attracting new innovative projects, no more than one project per year will be a renewal. The unique strengths of the Developmental Research Program lie in its ability to provide significant financial support in a timely manner to high-risk/pilot projects to develop critical preliminary data, provide a flexible mechanism that can respond rapidly to new initiatives or exciting findings through a formal application procedure using the Executive Committee and Internal Advisory Board, or receive even quicker but lesser funds through an ad hoc award from the Discretionary Fund of the RPCI-UPCI Ovarian Cancer SPORE Principal Investigator.
The Developmental Research Program of an NCI SPORE is the incubator of the cutting-edge, potentially paradigm-shifting research that will be tested to become the next generation standard-of-care. The RPCI-UPCI Ovarian Cancer SPORE will provide 2 complementary advantages as a mechanism for supporting translational research: 1) a constructive review process provided by the Executive Committee facilitates evolution of hypotheses, and 2) a rapid review and award procedure allows immediate and flexible funding of new ideas.
|Tsuji, Takemasa; Yoneda, Akira; Matsuzaki, Junko et al. (2018) Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy. Cancer Immunol Res 6:594-604|
|Shenoy, Gautam N; Loyall, Jenni; Maguire, Orla et al. (2018) Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses. Cancer Immunol Res 6:236-247|
|Soh, Kah Teong; Wallace, Paul K (2018) RNA Flow Cytometry Using the Branched DNA Technique. Methods Mol Biol 1678:49-77|
|Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377|
|Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459|
|Yang, Xi; Xia, Rui; Yue, Cuihua et al. (2018) ATF4 Regulates CD4+ T Cell Immune Responses through Metabolic Reprogramming. Cell Rep 23:1754-1766|
|Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320|
|Wang, Zehua; Yang, Bo; Zhang, Min et al. (2018) lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell 33:706-720.e9|
|Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035|
|Harris, Holly R; Babic, Ana; Webb, Penelope M et al. (2018) Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 27:174-182|
Showing the most recent 10 out of 128 publications